Accès ouvert
2026
conference-abstract
OpenAlex
Harrison David Winters, Thanh J. Nguyen, Reena S. Suresh, Ervin Griffin et autres
30 Background: While many patients with LARC experience durable responses after TNT, relapse risk remains a concern and is not reliably predicted by standard clinicopathologic measures. ctDNA is a promising biomarker for minimal residual disease (MRD) that could improve post-TNT risk-stratification and …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Peter Chi-Win Li, Harrison David Winters, Xue Geng, Hongkun Wang et autres
696 Background: ctDNA is a powerful tool that can detect MRD with limited but emerging data in patients (pts) with PDAC. We describe the clinical outcomes of pts with PDAC who underwent real-world MRD testing at our institutions. Methods: We retrospectively analyzed …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Harrison David Winters, Paul E. Sackstein, Benjamin Adam Weinberg, Dipanjan Debnath et autres
176 Background: ctDNA is a powerful tool that can detect early evidence of tumor relapse, or MRD. There are limited studies characterizing the performance of ctDNA in non-colorectal GI cancer patients (pts). We describe the clinical outcomes of GI cancer pts who …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Harrison David Winters, Paul E. Sackstein, Benjamin Adam Weinberg, Dipanjan Debnath et autres
e15518 Background: Circulating tumor DNA (ctDNA) is a powerful tool that can detect early evidence of cancer relapse, or MRD. While most GI MRD studies to date are in colorectal adenocarcinoma (AC), a limited but growing body of evidence supports its use …
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Reetu Mukherji, Ali Jaber Alqahtani, Harrison David Winters, Benjamin Adam Weinberg
Despite our modern perioperative therapies, many patients with gastrointestinal cancer relapse after surgery. Novel strategies to identify and treat patients at high risk of relapse are needed to improve cancer outcomes. Circulating tumour DNA (ctDNA) is a promising, non-invasive biomarker with the …
us
(code pays fourni par la source)